Weighted Average Number of Shares Outstanding, Diluted of Carisma Therapeutics Inc. from 31 Dec 2014 to 30 Sep 2025

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
Carisma Therapeutics Inc. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 31 Dec 2014 to 30 Sep 2025.
  • Carisma Therapeutics Inc. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Sep 2025 was 41,940,292, a 0.85% increase year-over-year.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2024 was 41,456,210, a 24% increase from 2023.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 33,524,197, a 1475% increase from 2022.
  • Carisma Therapeutics Inc. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 2,128,069, a 99% decline from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

Carisma Therapeutics Inc. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 41,940,292 +352,257 +0.85% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 41,788,096 +244,543 +0.59% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 41,771,213 +832,749 +2% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 41,456,210 +7,932,013 +24% 01 Oct 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
Q3 2024 41,588,035 +1,302,177 +3.2% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 41,543,553 +1,285,446 +3.2% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 40,938,464 +28,154,941 +220% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 33,524,197 +31,396,128 +1475% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 40,285,858 +38,096,593 +1740% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 40,258,107 +38,196,464 +1853% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 12,783,523 +10,723,537 +521% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 2,128,069 -180,194,931 -99% 01 Oct 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
Q3 2022 2,189,265 -198,827,735 -99% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 2,061,643 -173,331,357 -99% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 2,059,986 -154,973,014 -99% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 182,323,000 +64,102,000 +54% 01 Oct 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 201,017,000 +83,131,000 +71% 01 Jul 2021 30 Sep 2021 10-Q 07 Nov 2022 2022 Q3
Q2 2021 175,393,000 +62,824,000 +56% 01 Apr 2021 30 Jun 2021 10-Q/A 25 Aug 2022 2022 Q2
Q1 2021 157,033,000 +47,210,000 +43% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 118,221,000 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 117,886,000 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 112,569,000 +31,830,000 +39% 01 Apr 2020 30 Jun 2020 10-Q 09 Aug 2021 2021 Q2
Q1 2020 109,823,000 +32,365,000 +42% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q2 2019 80,739,000 01 Apr 2019 30 Jun 2019 10-Q 10 Aug 2020 2020 Q2
Q1 2019 77,458,000 01 Jan 2019 31 Mar 2019 10-Q 11 May 2020 2020 Q1
Q3 2017 24,691,000 +3,268,000 +15% 01 Jul 2017 30 Sep 2017 10-Q 17 Nov 2017 2017 Q3
Q3 2016 21,423,000 +2,078,000 +11% 01 Jul 2016 30 Sep 2016 10-Q 17 Nov 2017 2017 Q3
Q3 2015 19,345,000 01 Jul 2015 30 Sep 2015 10-Q 14 Nov 2016 2016 Q3

Carisma Therapeutics Inc. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 41,456,210 +7,932,013 +24% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 33,524,197 +31,396,128 +1475% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 2,128,069 -180,194,931 -99% 01 Jan 2022 31 Dec 2022 10-K 01 Apr 2024 2023 FY
2021 182,323,000 +64,102,000 +54% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2023 2022 FY
2020 118,221,000 +27,292,000 +30% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 90,929,000 +29,155,000 +47% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 61,774,000 +35,669,000 +137% 01 Jan 2018 31 Dec 2018 10-K 01 Mar 2019 2018 FY
2017 26,105,000 +4,372,000 +20% 01 Jan 2017 31 Dec 2017 10-K 01 Mar 2019 2018 FY
2016 21,733,000 +2,740,000 +14% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 18,993,000 +4,349,000 +30% 01 Jan 2015 31 Dec 2015 10-K 02 Apr 2018 2017 FY
2014 14,644,000 01 Jan 2014 31 Dec 2014 10-K 24 Mar 2017 2016 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.